|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A method for spatial–temporal forecasting with an application to real estate prices显示文摘 | R.Kelley Pace Ronald Barry Otis W. Gilley C.F. Sirmans | 2000 | International Journal of Forecasting2000，，2： | 2 |
| 2 | 丙烯酸酯橡胶的配合技术显示文摘汽车技术的当前趋向是不断提高性能、效率和成本效率。这些技术要求与全球大汽车制造商们在温度和担保方面所提出的新要求完全相符。因此,密封件、垫片和用于密封和传送最先进的汽车流体的胶管技术得到了持续的发展。瑞翁化学品公司(Zeon)在研发新型ACM(丙烯酸酯橡胶)技术方面不断创新,使丙烯酸酯橡胶实现了配炼安全,可用各种加工设备进行料斗贮存和硫化。这些研究成果最终导致了现代化丙烯酸酯橡胶配方的出现,这些配方具有理想的硫化速度,硫化胶具有卓越的物理性能和拉伸性能。生胶的选择是决定使用温度和耐油性能的主要因素。为特定的应用选择合适的聚合物是开发一种成功的丙烯酸酯胶料配方最为关键的一步。本文对每一种ACM聚合物的特性、不同硫化体系的特点以及丙烯酸酯橡胶在那些要求苛刻的应用上分别获得成功的例子进行了详细的介绍。本文还将对采用最新的丙烯酸酯技术获得的性能进行说明。 | 何敏 Joshua R.Kelley | 2014 | 现代橡胶技术2014，40，1： | 1 |
| 3 | 在耐高温耐油软管中采用高挤出加工性能的新型HT-ACM弹性体显示文摘高温丙烯酸酯弹性体(HT-ACM)HyTemp AR212XP已被证实能够提供比其它以丙烯酸为基料的弹性体,如高温乙烯丙烯酸酯弹性体(HT-AEM)更为优异的耐热性能和耐液体性能。HT-ACM弹性体能在一个较大的极端温度范围内工作,同时耐受一些极具腐蚀性的液体。不仅如此,HyTempAR212XP还被设计用于挤出工序,它能提高50%的挤出速率。HyTempAR212XP除具有上述优点外还兼具良好的抗撕裂性能和表面光洁度,为满足当今最苛刻环境需求而提高软管性能铺平了道路。 | 何敏 Peter J.Abraham Joshua R.Kelley Joseph D.Fields | 2014 | 现代橡胶技术2014，40，4： | 0 |
| 4 | CAMEL-CANAR Regulates PIN Trafficking and Polarity显示文摘Multicellular organisms maintain their growth and development in a dynamic and coordinated fashion.Cell polarity plays a key role in regulating cellular differentiation and proliferation during growth and development.In plants,several developmental processes such as embryogenesis,leaf venation,stomatal patterning,and phyllotaxy depend on establishment of cellular polarity.One of the best understood plant polarity proteins is the family of PINFORMED(PIN)auxin efflux carriers.PIN-mediated auxin transport has been central to a canalization hypothesis whereby auxin transport actively promotes vasculature formation and influences leaf venation patterns,but its exclusive role in the latter has been recently challenged(Verna et al.,2019).In the canalization hypothesis,positive feedback of auxin transport occurs in cells with increased auxin flux and leads to the establishment of auxin sinks within an organ(Sachs,1991). | M.Arif Ashraf Dior R.Kelley | 2021 | Molecular Plant2021，14，1： | 0 |
| 5 | N-烷基嘧啶DNA糖基化酶腺病毒提高人骨肉瘤化疗敏感性的研究显示文摘目的构建复制缺陷型腺病毒N-烷基嘧啶DNA糖基化酶(MPG)表达载体,观察人骨肉瘤细胞HOS过表达MPG及其对DNA损伤药物甲基甲磺酸酯(MMS)、N-甲基-N1-硝基-N-亚硝基鸟嘌呤(MNNG)和替莫唑胺(TMZ)敏感性的影响。方法应用流式细胞术、蛋白印迹和HEX标记寡核苷酸方法确定MPG腺病毒表达载体Ad5HA-MPG在人体骨肉瘤细胞HOS中的感染效率、MPG蛋白表达和MPG酶活性;MTS、硫氰酸盐B法和[3H]胸腺嘧啶掺入法检测经MMS(1、2μmol/L)、MNNG(25、50μmol/L)和TMZ(1、2mmol/L)处理过的转染细胞存活情况;PE-Annexinv/7-AAD流式细胞术检测细胞凋亡。结果10个感染增殖指数(MOI)的Ad5HA-MPG可使90%以上HOS感染,感染细胞高表达MPG并具有MPG酶活性。MPG过表达HOS显著地提高DNA损伤性化疗药物MMS、MNNG和TMZ的敏感性,其半数抑制浓度(IC50)值分别下降了6·0、4·5和2·5倍。结论Ad5HA-MPG瞬时MPG过表达,可能是一种提高骨肉瘤细胞对DNA损伤性化疗药物敏感性的潜在治疗方法。 | 王东 仲召阳 张沁宏 李增鹏 Mark R.Kelley | 2006 | 中华病理学杂志2006，35，6： | 0 |
| 6 | Challenges and opportunities identifying therapeutic targets for chemotherapy-induced peripheral neuropathy resulting from oxidative DNA damage显示文摘Background on chemotherapy-induced peripheral neuropathy(CIPN)Incidence,prevalence,and consequences:Up to 90%of cancer patients experience CIPN at some point during or after anticancer treatment(Seretny et al.,2014).Although CIPN is second to hematologic toxicities in regards to the frequency of incidence, | Mark R.Kelley Jill C.Fehrenbacher | 2017 | Neural Regeneration Research2017，12，1： | 0 |
| 7 | Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue显示文摘Market drugs,suchas Foodand Drug Administration(FDA)or European Medicines Agency(EMA)-approved drugs for specific indications provide opportunities for repurposing for newer therapeutics.This potentially saves resources invested in clinical trials that verify drug safety and tolerance in humans prior to alternative indication approval.Protein arginine methyltransferase 5(PRMT5)overexpression has been linked to promoting the tumor phenotype in several cancers,including pancreatic ductal adenocarcinoma(PDAC),colorectal cancer(CRC),and breast cancer(BC),making PRMT5 an important target for cancer therapy.Previously,we showed that PRMT5-mediated methylation of the nuclear factor(NF)-kB,partially contributes to its constitutive activation observed in cancers.In this study,we utilized an AlphaLiSA-based high-throughput screening method adapted in our lab,and identified one FDA-approved drug,Candesartan cilexetil(Can,used in hypertension treatment)and one EMA-approved drug,Cloperastine hydrochloride(Clo,used in cough treatment)that had significant PRMT5-inhibitory activity,and their anti-tumor properties were validated using cancer phenotypic assays in vitro.Furthermore,PRMT5 selective inhibition of methyltransferase activity was confirmed by reduction of both NF-kB methylation and its subsequent activation upon drug treatment.Using in silico prediction,we identified critical residues on PRMT5 targeted by these drugs that may interfere with its enzymatic activity.Finally,Clo and Can treatment have exhibited marked reduction in tumor growth in vivo.Overall,we provide basis for pursuing repurposing Clo and Can as anti-PRMT5 cancer therapies.Our study offers potential safe and fast repurposing of previously unknown PRMT5 inhibitors into clinical practice. | Lakshmi Prabhu Matthew Martin Lan Chen Ozlem Demir Jiamin Jin Xiumei Huang Aishat Motolani Mengyao Sun Guanglong Jiang Harikrishna Nakshatri Melissa L.Fishel Steven Sun Ahmad Safa Rommie E.Amaro Mark R.Kelley Yunlong Liu Zhong-Yin Zhang Tao Lu | 2023 | Genes & Diseases2023，10，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员